<DOC>
	<DOCNO>NCT01019850</DOCNO>
	<brief_summary>RATIONALE : Vorinostat may stop growth tumor cell block enzymes need cell growth . Radioactive drug , iobenguane I 131 , may carry radiation directly tumor cell harm normal cell . Giving vorinostat together iobenguane I 131 may kill tumor cell . PURPOSE : This phase I trial study side effect best dose give vorinostat together iobenguane I 131 treat patient resistant relapse neuroblastoma .</brief_summary>
	<brief_title>N2007-03 : Vorinostat 131-I MIBG Treating Patients With Resistant Relapsed Neuroblastoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine maximum tolerate dose vorinostat combination iobenguane I 131 patient resistant relapse neuroblastoma . - To define toxicity vorinostat combination therapeutic dos iobenguane I 131 patient . Secondary - To describe , within context phase I study , response rate patient treat vorinostat iobenguane I 131 . - To describe histone acetylation level norepinephrine transporter mRNA level peripheral blood mononuclear cell treatment different dos vorinostat . OUTLINE : This multicenter study . Patients receive oral vorinostat daily day 1-14 iobenguane I 131 IV 1Â½-2 hour day 3 . Patients undergo autologous peripheral blood stem cell transplantation day 17 . Blood sample may collect periodically correlative biological study . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>3-Iodobenzylguanidine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Patients must least 24 month old 30 year age register study . Patients must relapse neuroblastoma , refractory neuroblastoma less partial response standard treatment persistent neuroblastoma least partial response standard treatment . Patients least partial response standard treatment still neuroblastoma see CT/MRI MIBG scan must surgical biopsy do tumor confirm neuroblastoma . Patients relapse refractory neuroblastoma need biopsy do enter study . Patients must evidence MIBG uptake tumor one site within 4 week prior entry study subsequent intervening therapy . Patients must stem cell product available meet study criterion . If n't already stem cell frozen away must able stem cell collection do collect necessary amount stem cell study entry stem cell must meet study criterion . Patients must adequate heart , kidney , liver bone marrow function . Patients bone marrow disease must meet bone marrow function criterion enter study . They treatment 131IMIBG . They prior treatment vorinostat HDAC inhibitor . They stem cell transplant use another person stem cell donor . ( You still study previous transplant use stem cell ) They medical problem could get much bad treatment . They dialysis bad kidney function . They history unexplained blood clot , pulmonary embolus , thrombotic stroke , arterial clot . They pregnant breast feed . They active infection hepatitis fungal infection . They total body radiation radiation entire belly large amount radiation liver kidney ( radiation liver kidney ok ) . They ca n't cooperate special precaution need MIBG treatment .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>disseminate neuroblastoma</keyword>
	<keyword>localize unresectable neuroblastoma</keyword>
	<keyword>recurrent neuroblastoma</keyword>
	<keyword>regional neuroblastoma</keyword>
</DOC>